Dianaty Ali 4

What Happened

• Dianaty Ali, EVP & Chief Product & Technology Officer of MiniMed Group (MMED), was granted two derivative awards on March 9, 2026 totaling 140,152 units: 13,889 and 126,263. Both were reported as awards at a $0.00 per-share price (these are equity awards, not cash purchases).

Key Details

• Transaction date and price: March 9, 2026 — two awards totaling 140,152 units at $0.00 per unit (derivative securities).
• Award types and vesting notes:
  • 13,889 performance-based restricted stock units (RSUs). Per footnote: each RSU is a contingent right to one share and vests March 9, 2027 only if MMED common stock achieves a closing price of at least $32.05 as of the defined Divestment Date.
  • 126,263 derivative awards subject to later vesting; footnotes indicate vesting timing tied to the later of March 9, 2027 or the Divestment Date, and an additional schedule that vests 33% on each of March 9, 2028 and March 9, 2029 and 34% on March 9, 2030 (per filing).
• Shares owned after transaction: not provided in the excerpt of the filing you supplied.
• Filing timeliness: Reported on Form 4 filed March 11, 2026 for a March 9, 2026 transaction — within the usual two-business-day Form 4 reporting window (i.e., not late).

Context

• These are derivative awards (RSUs/options) granting contingent rights to receive common stock in the future if vesting conditions are met — not an immediate cash purchase or sale. Performance-based RSUs require a stock-price threshold ($32.05) by the specified Divestment Date to vest. Time-based portions vest over multiple years (2027–2030) per the filing. Such awards are common as executive compensation and do not by themselves indicate insider buying or selling intent.